Evidence map›Paper›PMID 41559511›Full record

ReviewDermatology and therapy2026

Oral JΑΚ Inhibitors in Vitiligo Treatment.

Angeliki Panagopoulou, Elena Sotiriou, Ilias Papadimitriou, Anastasios Pavlidis, Katerina Bakirtzi, Aikaterini Tsentemeidou, Michael Arabatzis, Efstratios Vakirlis, Dimitra Kiritsi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Angeliki PanagopoulouFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Elena SotiriouFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Ilias PapadimitriouFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anastasios PavlidisFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Katerina BakirtziFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aikaterini TsentemeidouFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Michael ArabatzisFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Efstratios VakirlisFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitra KiritsiFirst Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. dimkyritsi@auth.gr.ORCID http://orcid.org/0000-0002-2331-8981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionVitiligo is an acquired disorder of skin pigmentation characterized by impaired melanocyte function and the appearance of well-outlined, white skin spots. Worldwide the incidence ranges between 0.5% and 2%. It has a negative impact on the quality of life of patients causing anxiety, depression, and social stigma. This comprehensive review aims to consolidate the current evidence concerning vitiligo treatment with oral Janus kinase (JAK) inhibitors.

methodsThree databases (PubMed, Medline, and Embase) were searched to identify all articles discussing vitiligo treatment with oral JAK inhibitors up to April 2025.

resultsWe identified 217 articles encompassing vitiligo treatment with the JAK inhibitors baricitinib, tofacitinib, upadacitinib, ritlecitinib, ruxolitinib, prebocitinib, and povorcitinib. LIMITATIONS: The data primarily stem from observational studies, case reports, case series, pilot studies, reviews, and meta-analyses. The establishment of treatment protocols necessitates more extensive and well-controlled studies.

conclusionsOral JAK inhibitors could present an effective and safe option for patients with vitiligo; however. there is a need for further long-term studies and more data about treatment procedures.

Indexed as

BaricitinibJanus kinase inhibitorMelanocyte functionUpadacitinib

Identifiers

PMID41559511
PMCPMC12936231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.